San Francisco startup Framework Therapeutics is additionally working on an oral, when-daily GLP-1 drug identified as GSBR-1290—the drug surpassed Wall Avenue’s expectations in June every time a mid-stage research showed typical weight loss of all over six% and it programs to start A further mid-phase demo to the tip of this year—that founder